Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake.

The article argues UnitedHealth is improving despite medical cost pressure, citing a medical care ratio of 86.7% (down from 89.4% a year earlier) and an operating margin rising from 4.6% to 7.1% YoY. Management plans to invest $1.5–$1.6B in AI in 2026, including generative AI to automate claims/back office work; Optum Rx reports AI cutting call center volume by 25% and reducing prior authorization times to <30 seconds (from hours). It maintains a forecast for double-digit adjusted earnings growth in 2026, framing Tepper’s exit as an AI-focused rotation rather than a bearish judgment on UNH’s outlook.

Analysis

The market is likely overpaying for the headline risk and underpaying for the operating leverage. For a platform like UNH, incremental automation is not just cost cutting; it changes the slope of administrative expense growth, which matters more than one quarter of elevated medical trend. The real winners from this setup are the scaled insurers and care-service platforms with proprietary claims data; the losers are smaller managed-care peers that have to defend service levels while funding similar tech investments from a weaker cost base.

Near term, the stock still trades on medical cost prints and guidance credibility, not on AI narratives. The thesis breaks if the medical care ratio stays stuck in the high-86s/87s through the next two quarters or if management stops implying double-digit EPS growth for the next year. If, instead, claims automation continues to compress prior-auth and appeals friction, the bigger implication is SG&A leverage and retention stability, which should support multiple expansion over 6-18 months even if utilization remains elevated.

The consensus is missing that GLP-1 pressure and AI savings can coexist: one is a gross-cost headwind, the other is a process-margin tailwind. That makes this less of a simple quality-vs-growth debate and more of a relative-scale story. If investors insist on rotating into the AI theme Tepper is leaning into, the cleaner expression is infrastructure with pricing power and visible capacity monetization rather than cyclical memory exposure; the healthcare analog is owning the scale winner rather than fighting it.

Key Decisions for Investors

• Buy UNH on post-rally weakness for a 6-12 month hold; target a 12-15% re-rating if 2026 EPS guidance remains intact and medical cost ratio trends back toward the mid-80s.
• Pair trade: long UNH / short HUM or CI into the next healthcare print; the edge is scale-driven automation amortization versus smaller peers' weaker operating leverage.
• If rotating with the AI theme, prefer TSM over MU on a 3-6 month horizon; TSM has the cleaner demand-through-capacity transmission and less cycle risk than memory.
• Set a falsifier alert on UNH: if the medical care ratio fails to improve sequentially over the next two quarters or management trims 2026 growth targets, exit the thesis.